Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine

T

Trinity Hypertension & Metabolic Research Institute

Status and phase

Completed
Phase 4

Conditions

JNC 7 Stage 1 or 2 Hypertension

Treatments

Drug: Nebivolol I
Drug: Nebivolol II
Other: Baseline Washout Phase

Study type

Interventional

Funder types

Other

Identifiers

NCT03635125
BYS-MD-48

Details and patient eligibility

About

Study is to evaluate the effect of Nebivolol to treat high blood pressure compared to an already approved drug, Metoprolol ER with background treatment of Amlodipine.

Full description

Open-label, single center study consisting of a 2 to 4 week baseline washout phase, a 12-week Amlodipine background treatment phase followed by a 4-week Low Dose Nebivolol/Metoprolol Treatment phase and a 4-week High Dose Nebivolol/Metoprolol Treatment Phase.

Enrollment

40 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Capable of reading, comprehending the consent process and providing written informed consent to participate in the study.
  • Male or female equal/over 18 years of age.
  • Stage I-II hypertension defined as a baseline mean seated cuff Diastolic blood pressure of equal/over 95 mmHg and equal/less 115 mmHg and Systolic blood pressure equal/less to 180 mmHg at two consecutive qualifying visits during the placebo run in period.
  • Arm circumference less 45 cm
  • Compliance with single blind placebo capsules between V1-4 of 80-120%.

Women may be enrolled if all three of the following criteria are met:

  • Have a negative serum pregnancy test at screening
  • Are not breastfeeding

Do not plan to become pregnant during the study and if one of the three criteria is met:

  • Have had a hysterectomy or tubal ligation at least 6 months prior to signing the informed consent form
  • Have been postmenopausal for at least 1 year
  • Are of childbearing potential and will practice one the following methods of birth control throughout the study: oral, patch, injectable, or implantable hormone contraception, intrauterine device, diaphragm plus spermicide or female condom plus spermicide. Abstinence, partner's vasectomy are not acceptable methods of contraception.

Exclusion criteria

  • Known allergy or hypersensitivity to Beta Blockers.
  • Known allergy or hypersensitivity to Calcium Channel Blockers.
  • Patients with severe hypertension (mean seated cuff Diastolic blood pressure > 115 mmHg or mean seated Systolic blood pressure >180 mmHg) or any form of secondary hypertension.
  • Patients within the past 6 months with a history of hypertensive encephalopathy, stroke or transient ischemic attack.
  • Patients within the last 6 months with a history of myocardial infarction, percutaneous trans luminal coronary revascularization, coronary bypass graft, valvular surgery or unstable angina.
  • Patients with evidence of resting bradycardia (<50 bpm) via palpation.
  • Patients with a history of heart block greater than First Degree Sino atrial Block. Wolff-Parkinson-White Syndrome, Sick Sinus Syndrome, Atrial Fibrillation, Atrial Flutter, Congestive Heart Failure, or other manifestations of clinically significant cardiac valvular disease.
  • Patients with hemodynamically significant cardiac valvular disease.
  • Patients with evidence of significant chronic renal impairment as indicated by a serum creatinine of > 2.5mg/dL
  • Patients with evidence of liver disease as indicated by AST (SGOT) or ALT (SGPT) > 2.5 times or total bilirubin > 1.5 times, the upper limit of the laboratory normal range.
  • Patients who demonstrate other laboratory test values deviating from the Normal range which are considered to be clinically significant by the investigator.
  • Patient with a history or presence of gastrointestinal disease which may interfere with drug absorption.
  • Patients with insulin and non-insulin dependent diabetes mellitus not controlled on diet, insulin or oral hypoglycemic as defined by a HgA1c >10.
  • Severe psychological or emotional condition which may interfere with participation in the study.
  • History of or current use of illicit drugs or alcohol abuse.
  • Participation in a clinical trial and taking any investigation drug within 30 days prior to enrolling into the study (Screening Visit).
  • A physical condition that would limit accurate BP measurement.
  • Inability to swallow a tablet or capsule.
  • History of moderate or sever asthma or Chronic obstructive pulmonary disease.
  • Any other medical condition which, in the Investigator's opinion, may render the patient unable to complete the study or which would interfere with optimal participation in the study or produce significant risk to the patient.

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

40 participants in 4 patient groups

Background treatment phase
No Intervention group
Description:
A 12- week Amlodipine 10 mg background treatment phase
Low Dose Treatment Phase-Nebivolol I
Active Comparator group
Description:
4-week low dose Nebivolol10 mg/Metoprolol 50 mg treatment phase
Treatment:
Drug: Nebivolol II
Drug: Nebivolol I
High dose treatment Phase-Nebivolol II
Active Comparator group
Description:
4-week High dose Nebivolol 20 mg/Metoprolol 100mg treatment phase
Treatment:
Drug: Nebivolol II
Drug: Nebivolol I
Baseline Washout Phase
Other group
Description:
2 to 4 week Baseline Washout Phase
Treatment:
Other: Baseline Washout Phase

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems